Approximate annual Medicare fee-for-service payment reductions modeled nationally
Financial Intelligence · Proposed CY2027 policy
Know what CY2027 Medicare payment changes could cost your practice.
National estimates tell you there is a problem. We show you where the financial exposure sits inside your organization.
ClinEfficiency Pro analyzes your claims and remittance data against proposed and finalized Medicare payment-policy changes to quantify exposure by clinician, service, location and payment mechanism.
ClinEfficiency Pro analysis
Our analysis identified the exposure before the headline.
ClinEfficiency Pro independently analyzed CMS CY2027 payment modeling and utilization data to identify specialties and services with concentrated exposure to the proposed Modifier 25 payment change. Our current specialty comparison identifies particularly strong exposure signals in otolaryngology/ENT, dermatology, podiatry and orthopedics, while also demonstrating that exposure varies materially by specialty and service mix.
ClinEfficiency Pro proprietary CMS-data modeling
CEP CY2027 Modifier 25 Exposure Signal
Modeled reduction volume as a percentage of the specialty service base. CMS CY2027 proposed-rule utilization data; not estimated practice revenue loss.
ENT / Otolaryngology
Dermatology
Podiatry#3
Orthopedics
Urology
Ophthalmology
Cardiology composite
Podiatry ranks third in ClinEfficiency Pro's modeled exposure signal at 5.80%, slightly above orthopedics. Public aggregate utilization establishes a specialty-level signal; organization-specific financial exposure requires encounter-level claims and remittance data.
- CMS specialty
- 48
- Modeled service base
- 25,981,853
- Reduction volume
- 1,506,841
- Affected-row volume
- 21,952,025 · 84.49%
Largest affected-volume CPT/HCPCS rows
- 11721~5.29M
- 99213~4.64M
- 11056~1.85M
- 11720~1.78M
- 99214~987K
- 99203~982K
- G0127~926K
- 99212~766K
- 11055~753K
- 11042~642K
Reproduced against CMS-1848-P “2025 Utilization Data Crosswalked to 2027” and validated by reproducing previously saved specialty results. Exposure signal = modeled Modifier 25 proposal reduction volume divided by modeled specialty service base. It is not estimated practice revenue loss.
Why now
A national estimate isn't a financial plan.
CMS's proposed CY2027 Physician Fee Schedule includes a payment change affecting certain same-day office/outpatient E/M and procedural services when Modifier 25 is used with procedures carrying a 0-, 10-, or 90-day global period. Under the proposal, the highest-valued qualifying service would be paid in full and each other qualifying service would be reduced by 50%.
Proposed — not final
CMS-1848-P remains a proposal. Any finalized changes would take effect January 1, 2027.
Independent market validation — Becker's / Jiro Health
81.5% of modeled reductions attributed to private practices and solo physicians
82.3% of modeled reductions concentrated across six specialties
44.5% of modeled reductions attributed to dermatology
Becker's ASC Review subsequently reported Jiro Health's claims-level analysis of deidentified Medicare fee-for-service claims from October 2024 through September 2025 across 67,018 billing providers. Jiro's national claims analysis is methodologically distinct from ClinEfficiency Pro's CMS-data modeling and provides independent market validation of the magnitude and concentration of the proposed payment exposure.
These are national modeled estimates, not estimates of any individual practice's loss. The ClinEfficiency Pro and Jiro Health percentages are distinct measures and are not directly comparable. Aggregate data cannot tell an organization which encounters create exposure, which clinicians or locations drive it, or what the change means for operating margin. That is the gap this diagnostic closes.
Source: Becker's ASC Review, “Private practices would absorb 80% of Modifier 25 cuts: Analysis”, reporting Jiro Health's analysis of deidentified Medicare fee-for-service claims from October 2024 through September 2025 across 67,018 billing providers.
Client-specific paid claims/remittance analysis
From policy change to organization-specific financial exposure
Using 12 months of authorized claims and remittance data for one billing entity, ClinEfficiency Pro evaluates:
- Qualifying same-day E/M + procedure encounters
- Actual Modifier 25 utilization and service-pair patterns
- CPT/HCPCS and global-period combinations
- Allowed amounts
- Exposure by clinician, specialty, location/POS and service pair
- Low/base/high financial scenarios under the proposed policy
- Modifier 25 impact separated from other CY2027 professional payment changes
What you receive
You receive decision intelligence, not another policy summary.
Executive Exposure Summary
Estimated annualized revenue exposure and concentration.
Provider & Service Heat Map
Clinicians, locations and service combinations driving exposure.
Payment Bridge
Isolates the proposed Modifier 25 policy effect from broader CY2027 changes.
Management Priorities
Identifies areas warranting operational, coding, scheduling and site-of-service review.
Final-Rule Refresh
One update after CMS finalizes the relevant policy.
Engagement
Fixed-fee diagnostic: $7,500
One billing entity. Twelve months of claims/remittance data. One decision-ready analysis.
Includes executive readout and one final-rule refresh.
Who may be most affected?
Which practices and specialties may be most affected?
Becker's ASC Review reported that Jiro Health's national claims analysis concentrated modeled reductions across the following six specialties. Organizations with frequent same-day office/outpatient E/M services and procedures may have greater exposure.
Priority organizations include independent and multi-site podiatry, dermatology, ENT, orthopedic and selected ophthalmology physician enterprises. Family medicine remains in the screening universe based on the independent national claims analysis.
- Dermatology — approximately $395.4 million, or 44.5%, of modeled national reductions
- Podiatric medicine and surgery
- Orthopedic surgery
- Otolaryngology / ENT
- Ophthalmology
- Family medicine
Together, these six specialties account for approximately $732 million, or 82.3%, of Jiro's modeled national reductions.
$724.4M
Private practices and solo physicians account for approximately 81.5% of Jiro's modeled national reductions.
Your specialty isn't the test. Your claims are.
Other specialties may also have meaningful exposure depending on their mix of same-day E/M and procedures. Specialty averages cannot determine what an individual organization will experience.
The CY2027 Professional Payment Exposure Diagnostic measures your organization's actual claims patterns to determine where — and how much — exposure exists.
Start with your claims
Replace a national headline with an organization-specific decision.
This is analytical and management decision support, not legal advice and not a guarantee of reimbursement outcomes. ClinEfficiency Pro does not claim a specific organization has exposure until its own authorized claims data has been analyzed.